Aegerion Pharmaceuticals, Inc. (AEGR) 10-Q Quarterly Report November 2015

Cambridge, MA, November 9, 2015 - Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced its financial results and business highlights for the third quarter of 2015.

Highlights

Aegerion recorded total net product sales of $67.3 million in the third quarter of 2015.

Aegerion recorded $58.8 million in net product sales of JUXTAPID® (lomitapide) capsules in the third quarter of 2015, $49.6 million of which was from prescriptions written in the United States.

Aegerion recorded $8.5 million in net product sales of MYALEPT® (metreleptin for injection) in the third quarter of 2015, which includes a $700,000 sale of inventory to Shionogi for distribution in Japan, South Korea and Taiwan. As of October 30, 2015, 78 generalized lipodystrophy (GL) patients were active on commercial therapy, an increase of 10 patients from July 31, 2015.

Aegerion generated $14.7 million of cash in the third quarter of 2015.

Aegerion obtained pricing and reimbursement approval for LOJUXTA® (lomitapide) in the Netherlands through the Dutch Ministry of Health.

Aegerion is on track with its plan to file a Japanese NDA for lomitapide in adult HoFH patients in early 2016. Aegerion anticipates a nine month review period as a result of lomitapide’s orphan drug status.

Chief Executive Officer Sandford D. Smith commented, “In the third quarter, we executed well on a number of Aegerion’s key strategic objectives by maintaining a strong focus on our current commercial products and progressing towards broader market access for LOJUXTA in Europe. We are managing JUXTAPID through volatile market dynamics associated with the introduction of PCSK9 inhibitors. In addition, we continue to identify generalized lipodystrophy patients and bring them on to MYALEPT. We view MYALEPT as an important and steady growth driver.

“We made progress towards supporting the long-term growth of Aegerion through a strategic plan that prioritizes Aegerion’s life cycle management and business development initiatives. Deepening Aegerion’s pipeline with opportunities for both MYALEPT and JUXTAPID, as well as potential new assets, remains an important objective. We expect that these efforts, combined with our ongoing expansion into both European and other international markets, will support meaningful future growth.”

The following information was filed by Aegerion Pharmaceuticals, Inc. (AEGR) on Monday, November 9, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-Q report or click the link below:

https://last10k.com/sec-filings/report/1338042/000155837015002514/aegr-20150930x10q.htm

View differences made from one quarter to another to evaluate Aegerion Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Aegerion Pharmaceuticals, Inc..

Continue

Assess how Aegerion Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Aegerion Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2015 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Material Contracts, Statements, Certifications & more

Aegerion Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 10.1: Material Contract

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: AEGR
CIK: 1338042
Form Type: 10-Q Quarterly Report
Accession Number: 0001558370-15-002514
Submitted to the SEC: Mon Nov 09 2015 4:15:11 PM EST
Accepted by the SEC: Mon Nov 09 2015
Period: Wednesday, September 30, 2015
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/aegr/0001558370-15-002514.htm

Aegerion Pharmaceuticals, Inc. (AEGR) SEC Filing 10-Q Quarterly report for the period ending Wednesday, September 30, 2015

SEC Filings

AEGR Valuations

AEGR Annual Reports

AEGR Quarterly Reports

AEGR Corporate News